Basic Information

Drug ID DDPD00541 ...
Drug Name Vincristine
Molecular Weight 824.972
Molecular Formula C46H56N4O10
CAS Number 57-22-7
SMILES [H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC
External Links
DRUGBANK DB00541
T3DB T3D4016
PubChem Compound 5978
PDR 2577
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 2.82 - 2.82 - HANSCH,C ET AL. (1995)
Melting Point 220.0 220 PhysProp
pKa 5.0 - 5 - MERCK INDEX (1996)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
C Max 278.4 ng/ml ~250-425 nM intravenous injection, IV; The Pharmacological Basis of Therapeutics
Clearance 4.9 L/h/m2 4.92±3.01 L/h/m2 tumor; patients; Male, men;  Female, women; Bile excretion; hydrolysis; Children → ;hepatopathy,LD ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.12 L/h/kg 2 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 96.6 L/m2 96.6±55.7 L/m2 tumor; patients; Male, men;  Female, women; Bile excretion; hydrolysis; The Pharmacological Basis of Therapeutics
Volume of Distribution 2.4 L/kg 2.4 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 0.0833 h 5 min distribution half-life; intravenous injection, IV; tumor; patients; DRUGBANK
Half-life 2.3 h 2.3 h elimination half-life; intravenous injection, IV; tumor; patients; DRUGBANK
Half-life 85.0 h 85 h terminal half-life; intravenous injection, IV; tumor; patients; DRUGBANK
Half-life 87.0 h 19-155 h terminal half-life; human, homo sapiens; DRUGBANK
Half-life 22.6 h 22.6±16.7 h chronic liver disease ↑ ; The Pharmacological Basis of Therapeutics
Half-life 85.0 h ~85±69 h The Pharmacological Basis of Therapeutics
Half-life 23.0 h 23 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 1300.0 mg/kg 1300.0 mg/kg intravenous injection, IV; Rattus, Rat; DRUGBANK
Toxicity LD50 5.2 mg/kg 5.2 mg/kg Intraperitoneal, IP; mouse; DRUGBANK
Toxicity LD50 1300.0 mg/kg 1300.0 mg/kg intravenous injection, IV; Rattus, Rat; T3DB
Toxicity LD50 5.2 mg/kg 5.2 mg/kg Intraperitoneal, IP; mouse; T3DB
Eliminate Route 80.0 % 80 % Faeces excretion; DRUGBANK
Eliminate Route 15.0 % 10-20 % Urinary excretion; DRUGBANK
Eliminate Route 15.0 % 10-20 % Urinary excretion; adults; tumor; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 75.0 % ~75 % DRUGBANK

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Frequency Brand Name Component Reference
Max dose for adults 2.25 mg/m2 2.25 mg/m2 intravenous injection, IV qw Marqibo vincristine sulfate liposome PDR
Max dose for geriatric 2.25 mg/m2 2.25 mg/m2 intravenous injection, IV qw Marqibo vincristine sulfate liposome PDR
Max dose for infants 2.0 mg/m2/week 2 mg/m2/week intravenous injection, IV qw Vincristine Sulfate vincristine sulfate PDR
Max dose for infants 0.00714285714285714 mg/kg/day 0.05 mg/kg/week intravenous injection, IV qw Vincristine Sulfate vincristine sulfate PDR
Max dose for children 2.0 mg/m2 2 mg/m2 intravenous injection, IV qw Vincristine Sulfate vincristine sulfate PDR
Max dose for adolescents 2.0 mg/m2 2 mg/m2 intravenous injection, IV qw Vincristine Sulfate vincristine sulfate PDR
Max dose for adults 1.4 mg/m2 1.4 mg/m2 intravenous injection, IV qw Vincristine Sulfate vincristine sulfate PDR
Max dose for geriatric 1.4 mg/m2 1.4 mg/m2 intravenous injection, IV qw Vincristine Sulfate vincristine sulfate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1